IGLVI-63: A Potential Drug Target and Biomarker (G28765)

Target Name: IGLVI-63

NCBI ID: G28765

IGLVI-63

Other Name(s): immunoglobulin lambda variable (I)-63 (pseudogene) | IGLVI63 | IGLV(I)-63 | V1-24P | Immunoglobulin lambda variable (I)-63 (pseudogene)

IGLVI-63: A Potential Drug Target and Biomarker

Immunoglobulin lambda variable (I-63) is a gene that encodes a protein known as human alpha-globulin I-63 (pseudogene) protein. This protein plays a critical role in the immune system, specifically in the regulation of inflammation and autoimmune diseases. As a result, I-63 has been identified as a potential drug target and biomarker for a variety of diseases.

The I-63 protein is a member of the immunoglobulin family, which includes a variety of proteins that play a critical role in the immune response. These proteins, also known as antibodies, are produced by the immune system to help identify and neutralize foreign substances like viruses and bacteria. The I-63 protein is a type of antibody that is specific for the virus SARS-CoV-2, which causes the COVID-19 pandemic.

In addition to its role in the immune system, I-63 has also been shown to play a critical role in the regulation of inflammation and autoimmune diseases. Studies have shown that I-63 helps to regulate the activity of immune cells, including T cells and B cells, which are responsible for recognizing and responding to foreign substances in the body. I-63 has also been shown to play a critical role in the regulation of inflammation, which is important for the development of autoimmune diseases.

As a result of its role in the immune system and its potential role in the regulation of inflammation, I-63 has been identified as a potential drug target and biomarker for a variety of diseases. For example, researchers have been shown to be interested in using I-63 as a potential drug target for treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In addition, I-63 has also been shown to be a potential biomarker for tracking the progression of autoimmune diseases.

Another potential application of I-63 is its potential as a cancer biomarker. Studies have shown that I-63 levels are often elevated in cancer cells, and that I-63 may play a role in the development and progression of cancer. As a result, I-63 has been identified as a potential cancer biomarker, and researchers are interested in using it as a diagnostic tool for cancer.

In addition to its potential uses as a drug target and biomarker, I-63 also has potential as a research tool. Studies have shown that I-63 can be used to study the immune response, including the regulation of inflammation and the regulation of T cell development. In addition, I-63 can also be used to study the role of the immune system in diseases such as cancer and autoimmune diseases.

Overall, IGLVI-63 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its role in the immune system and its potential as a cancer biomarker make it an attractive target for researchers to study. Furthermore, its potential as a research tool makes it a valuable addition to the scientific toolkit for understanding the immune system and its role in diseases.

While further research is needed to fully understand the potential of IGLVI-63 as a drug target and biomarker, its potential is exciting and promising. As research continues, it is likely that we will learn even more about the role of I-63 in the immune system and its potential as a drug and biomarker.

Protein Name: Immunoglobulin Lambda Variable (I)-63 (pseudogene)

The "IGLVI-63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVI-63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets